Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODM-216 first-in-human safety, pharmacokinetics, and preliminary antitumor activity trial in advanced solid tumours
2026-525864-17-00Phase 2Authorised
- Sponsor
- Orion Corporation
- Start
- Aug 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, single-arm trial of ODM-216 in Nonhematologic neoplasms, sponsored by Orion Corporation. Planned start Aug 2026; status: authorised.
02
Drugs
ODM-216
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2026-525864-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525864-17-00.